Henry Schein, Inc. $HSIC Holdings Cut by Strs Ohio

Strs Ohio lowered its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 91.5% in the third quarter, HoldingsChannel reports. The institutional investor owned 2,580 shares of the company’s stock after selling 27,665 shares during the period. Strs Ohio’s holdings in Henry Schein were worth $171,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of HSIC. Artisan Partners Limited Partnership raised its holdings in shares of Henry Schein by 0.9% during the second quarter. Artisan Partners Limited Partnership now owns 6,462,204 shares of the company’s stock worth $472,064,000 after acquiring an additional 55,653 shares in the last quarter. Ameriprise Financial Inc. increased its position in Henry Schein by 3,275.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after purchasing an additional 2,199,695 shares during the last quarter. Schroder Investment Management Group raised its stake in shares of Henry Schein by 149.3% during the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock worth $114,243,000 after purchasing an additional 936,471 shares in the last quarter. Swedbank AB lifted its holdings in shares of Henry Schein by 12.4% during the 3rd quarter. Swedbank AB now owns 1,299,571 shares of the company’s stock valued at $86,253,000 after buying an additional 143,173 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Henry Schein in the 2nd quarter valued at approximately $89,476,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on HSIC shares. Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Mizuho set a $81.00 price target on shares of Henry Schein and gave the stock a “neutral” rating in a research note on Tuesday, January 20th. Wells Fargo & Company lifted their price objective on shares of Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 5th. Morgan Stanley increased their target price on shares of Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a research report on Wednesday, November 5th. Finally, JPMorgan Chase & Co. boosted their price target on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Five analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Henry Schein currently has an average rating of “Hold” and a consensus target price of $76.42.

Henry Schein Trading Down 2.9%

Henry Schein stock opened at $73.14 on Wednesday. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $82.49. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.79 and a current ratio of 1.40. The firm has a market capitalization of $8.61 billion, a PE ratio of 23.15, a PEG ratio of 2.24 and a beta of 0.88. The business’s 50-day simple moving average is $76.26 and its 200-day simple moving average is $70.87.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.11. The firm had revenue of $3.34 billion for the quarter, compared to analyst estimates of $3.28 billion. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%. Equities research analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.